Qualitative Research on Global Lung Cancer Therapeutics Industry 2021 oct-21-2016 | Page 2

Global Lung Cancer Therapeutics Market According to the report "Lung Cancer Therapeutics Market", published by Market Data Forecast, the global market is projected to reach USD 7.81 Billion by 2021, at a CAGR of 6.7% from 2016 to 2021. For full report refer to “http://www.marketdataforecast.com/market-reports/global-lung-cancertherapeutics-market-893/” Lung cancer is a malignant lung carcinoma which is characterized by irregular cell growth in lung tissue. As the tumour grows in size, it reduces the lungs’ ability to provide oxygen to arteries, veins and capillaries. It is the common cause of mortality and illness not only in developed countries but also in developing countries. Smoking is thought as a main cause of lung cancer, though lung cancer also follows in non-smokers. Free sample for the report is available at “http://www.marketdataforecast.com/marketreports/global-lung-cancer-therapeutics-market-893/request-sample” Air pollution, amplified alcohol consumption, varying life style, smoking, unhealthy food, and no physical activity are the factors indirectly driving the market. Governments in the developing economies are providing awareness among the people about the cancer. As the geriatric population is likely to increase, the incidence of lung cancer is predicted to rise, thus acting as a driver for revenue growth. Global market for Lung Cancer Therapeutics is segmented on the basis of By Treatment Type and By Geography By Treatment Type:    Chemotherapy  Cisplatin  Taxol  Navelbine  Camptosar  Alimta Radiotherapy  External Beam  Internal Beam  Systemic Drugs Type  Abraxane  Avastin  Crizotinib  Docetaxel  Gefitinib By Geography:      North America Europe Asia-Pacific Latin America Middle-East and Africa [phone] | www.marketdataforecast.com | [email protected]